(ORDO NEWS) — The US Food and Drug Administration ( FDA) has approved Inmazeb for mass use.
Monoclonal Antibody Cocktail Becomes First Approved Drug for Ebola
The first formally accepted for mass use remedy for the deadly Ebola fever got Certified by the US Food and Drug Administration (FDA). About a year ago, the European Commission approved the Ervebo vaccine, but it is still being tested, like a number of other vaccines around the world. Inmazeb, approved for use, was developed by the American company Regeneron Pharmaceuticals.
The drug is a cocktail of three monoclonal antibodies that bind glycoprotein molecules on the surface of viral particles and thus prevent their penetration into host cells. When tested in 2018-2019, the drug showed good effectiveness, reducing mortality from Ebola from 51 to 34%. The Biomedical Advanced Research and Development Administration (BARDA) of the US Department of Health is organizing a national reserve for Inmazeb.
Ebola outbreaks are still most common in western Africa. On July 1, a new outbreak was reported in the Congo – the 11th in the described case history. According to the WHO, by the beginning of September, more than a hundred people fell ill and 47 of them died. Untreated, mortality from Ebola averages around 50%, although sometimes as high as 90%. The previous outbreak of 2018-2020 killed almost 2,300 people – 65% of those infected.
The Ebola virus was first identified in the equatorial province of Sudan and adjacent areas of Zaire (now the Democratic Republic of the Congo) in 1976. In Sudan, 284 people fell ill, 151 of them died, in Zaire – 318, 280 died. In its morphological properties, the virus is similar to the Marburg virus, but differs in antigenic terms. Both of these viruses belong to the filovirus family.
Contact us: [email protected]